Stereotaxis, Inc.
STXS NYSE· Electromedical & Electrotherapeutic Apparatus
Last close · Oct 23, 2026
$1.02
KIRA · Stoqly’s AI analyst, in plain words
- Stereotaxis, Inc. had $32.4M of revenue in fiscal 2025, up 20.3% on the year before. Over five years, revenue changed +4.0% a year on average.
- Its operating margin was −68.3%, up 23.6 pts: of every 100 in sales, about −68 is left after running the business.
- Stereotaxis, Inc. lost $21.6M in fiscal 2025.
- Free cash flow was −$13.8M in fiscal 2025, −42.6% of revenue.
- Stereotaxis, Inc. returned $0.0M to shareholders in fiscal 2025. The diluted share count rose 6.8%.
Market cap
$102M
P/E
—
Revenue
$32.4M
Net income
−$21.6M
Free cash flow
−$13.8M
Operating margin
−68.3%
Stereotaxis, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+20.3%
Yes. Sales grew 20.3% last year.
Does it make a profit?
−66.8%
No. It lost money last year.
Does profit turn into cash?
−42.6%
No. It spent more cash than it brought in.
How healthy are the accounts?
4 / 8
Mixed. It passes 4 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Stereotaxis, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 12, 2026
- Legal name
- Stereotaxis, Inc.
- CIK
- 0001289340
Stereotaxis, Inc. · STXS
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $35.0M | $28.1M | $26.8M | $26.9M | $32.4M |
| Revenue growth | 31.5% | −19.6% | −4.9% | 0.5% | 20.3% |
| Net interest income | −$0.0M | $0.5M | $1.1M | $0.7M | $0.5M |
| Gross margin | 66.3% | 65.6% | 55.5% | 54.2% | 52.7% |
| Operating margin | −36.8% | −66.7% | −81.6% | −91.9% | −68.3% |
| Net income | −$10.7M | −$18.3M | −$20.7M | −$24.0M | −$21.6M |
| Net margin | −30.6% | −65.0% | −77.4% | −89.3% | −66.8% |
| Diluted EPS | −$0.16 | −$0.26 | −$0.27 | −$0.30 | −$0.25 |
| Cash | |||||
| Cash from operations | −$2.9M | −$8.4M | −$9.1M | −$8.5M | −$13.7M |
| Capital expenditure | $1.4M | $2.4M | $0.4M | $0.0M | $0.1M |
| Free cash flow | −$4.3M | −$10.8M | −$9.5M | −$8.5M | −$13.8M |
| FCF margin | −12.4% | −38.3% | −35.5% | −31.7% | −42.6% |
| Dividends paid | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Share count change | 3.9% | 0.7% | 6.1% | 5.6% | 6.8% |
| Debt and strength | |||||
| Cash and short-term investments | $38.7M | $28.4M | $19.8M | $12.2M | $13.4M |
| Shareholders' equity | $33.8M | $26.3M | $16.3M | $6.1M | $13.5M |
| Current ratio | 3.9x | 3.0x | 2.5x | 1.2x | 1.5x |
| Returns and quality | |||||
| Return on equity | −31.3% | −60.8% | −97.0% | −214.5% | −221.3% |
| Return on tangible equity | −35.6% | −74.5% | −135.0% | — | −696.9% |
| Piotroski F-score | 2 | 1 | 2 | 1 | 4 |
| Altman Z'' | −22.3 | −29.1 | −41.3 | −41.9 | −37.4 |
Insiders bought, 12 months
$0.1M
1 insider
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Stereotaxis, Inc. · STXS
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.02 a share, the company is worth $102M.
Source: SEC EDGAR XBRL filings (CIK 0001289340). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.